Cardiopulmonary dysfunctions caused by ADP-induced platelet aggregation

Area of Science:

• Cardiovascular Physiology
• Hematology
• Pharmacology

Background:

• Adenosine diphosphate (ADP) is a key mediator in platelet activation and aggregation.
• Understanding ADP's systemic effects is crucial for cardiovascular and hematological research.

Purpose of the Study:

• To investigate the physiological effects of intravenous ADP administration in rats.
• To elucidate the mechanisms underlying ADP-induced cardiopulmonary and hematological changes.

Main Methods:

• Intravenous injection of ADP (0.1 mg/kg) in rats.
• Monitoring of platelet count, mean arterial pressure, central venous pressure, arterial PO2, heart rate, and respiration.
• Comparative studies involving splenectomy, busulfan treatment (inducing thrombocytopenia/leukopenia), and intra-arterial vs. intravenous administration.
• Dose-response and interval-dependency studies with repeated ADP injections.

Main Results:

• Intravenous ADP caused a rapid, significant drop in platelet count and induced bradycardia, hypotension, altered respiration, and increased central venous pressure.
• These effects were abolished in thrombocytopenic rats but not prevented by splenectomy.
• Intra-arterial injection yielded minimal response, and repeated injections at short intervals showed diminished effects.
• Longer intervals between injections restored the response.

Conclusions:

• Intravenous ADP induces transient microvascular obstruction, likely via platelet aggregates, leading to observed cardiopulmonary disturbances.
• The diminished response to successive injections is attributed to reduced platelet availability or induced refractoriness.
• ADP is rapidly metabolized in systemic circulation.